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782 The Journal of Thoracic and CardioBackground: Thrombocytopenia and platelet dysfunction are major mechanisms of
cardiopulmonary bypass–induced postoperative hemorrhage. This study evaluated
the effects of low amounts of nitric oxide, iloprost (prostacyclin analog), and their
combination administered directly into the oxygenator on platelet function, platelet-
leukocyte interactions, and postoperative blood loss in patients undergoing coronary
artery bypass grafting.
Methods: Blood samples from 41 patients randomized to the control, nitric oxide (20
ppm), iloprost (2 ng · kg1 · min1), or nitric oxide plus iloprost groups were collected
during cardiopulmonary bypass. Platelets and leukocytes were enumerated. Platelet
membrane glycoprotein Ib and glycoprotein IIb/IIIa, P-selectin, platelet-derived micro-
particles, leukocyte CD11b/CD18 (Mac-1), and platelet-leukocyte aggregate were quan-
tified by means of flow cytometry. Collagen and thrombin receptor-activating peptide–
induced platelet aggregation in whole blood was analyzed by means of aggregometry.
Results: Both nitric oxide or iloprost attenuated cardiopulmonary bypass–induced
thrombocytopenia, reduction of glycoprotein Ib and glycoprotein IIb levels, transloca-
tion of P-selectin, microparticle formation, Mac-1 upregulation, and suppression of
collagen-induced aggregation. Nitric oxide plus iloprost was significantly more effective
in preventing thrombocytopenia, microparticle formation, and P-selectin translocation.
Moreover, this treatment preserved thrombin receptor-activating peptide–induced ag-
gregation, which was not rescued by single treatments. Both nitric oxide and nitric oxide
plus iloprost attenuated postoperative blood loss.
Conclusions: Nitric oxide plus iloprost reduced the deleterious effects of cardiopul-
monary bypass, such as thrombocytopenia, platelet activation, platelet-leukocyte
aggregate formation, and suppression of platelet aggregative responses. The reduced
postoperative bleeding observed with this treatment suggests that this is a new and
clinically feasible therapeutic option for patients subjected to cardiopulmonary
bypass.
The development of cardiopulmonary bypass (CPB) has been one ofthe most important advancements in cardiac surgery. However, CPBis associated with thrombocytopenia, which is caused by activationand consumption of platelets, and leukocytosis. These reactions areresponsible for some adverse effects of the procedure, includingbleeding and systemic inflammation.1,2 The pathophysiologic effects
of platelet activation induced by CPB are still poorly understood. However, forma-
tion of platelet-leukocyte aggregates (PLAs) in the presence of artificial surfaces of
vascular Surgery ● April 2005
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Pthe CPB circuit might be an important mechanism of throm-
botic and inflammatory complications caused by CPB. The
development of selective therapeutic strategies to preserve
the function of platelets and leukocytes could reduce post-
operative hemorrhage, systemic inflammation, and vascular
dysfunction, with subsequent requirement for transfusion of
blood products and inotropes. This might have a significant
effect on patient morbidity and mortality.3 Nitric oxide
(NO) gas, prostacyclin (PGI2), and iloprost, a stable analog
of PGI2, are potent inhibitors of platelet activation in vitro
and in vivo4; however, their effects on specific platelet and
leukocyte receptors have not been comprehensively studied
in the setting of CPB. We designed a pilot clinical study to
investigate changes in platelet and leukocyte functions in
TABLE 1. Patient demographics and postoperative clinica
Characteristics Control
Sample size 18
Age (y) 61 12
Weight (kg) 86.2 3.7
Height (cm) 174 8.2
NYHA class 2.2 0.8
Number of CAD risk factors per patient 2.2
CAD risk factors
Diabetes, n (%) 8 (44)
Hypertension, n (%) 10 (56)
Hyperlipidemia, n (%) 5 (28)
History of smoking, n (%) 12 (67)
Hyperuremia, n (%) 4 (22)
Alcohol, n (%) 2 (11)
CCS class 2.6 0.9
Ejection fraction (%) 51 9
Pump time (min) 104 16
Clamp time (min) 68 18
Flow (L/min) 4.8 0.3
p max
1 min 121 110
30 min 118 87
60 min 97 33
End of pump 92 27
No. of grafts 3.3 0.6
Inotropic support
Epinephrine (g · kg1 · min1) 0.6  0.5
Norepinephrine (g · kg1 · min1) 0.3  0.2
Hemoglobin after CPB (g/dL) 10.3 4.04
Intraoperative RBCs (units/patient) 0.9 0.6
Postoperative RBCs given (units/patient) 3.4 1.6
Postoperative FFP given (units/patient) 1.8 0.7
Postoperative platelets given (units/patient) 0 0
Time to extubation (h) 12 3.3
ICU stay (h) 22.8 4.2
Methemoglobin (%) 0.26 0.1
NO, Nitric oxide; PGI2, prostacyclin; NYHA, New York Heart Association
cardiopulmonary bypass; RBCs, red blood cells; FFP, fresh frozen plasmapatients subjected to CPB. Furthermore, we studied the
The Journal of Thoracipotential protective effects of NO and iloprost on platelets
and leukocytes when administered directly into the oxygen-
ator of the CPB circuit. Moreover, we examined clinical
outcome parameters, such as thrombocytopenia and postop-
erative bleeding, to account for the pharmacodynamic ef-
fects of both drugs. The results of this study show that
combined therapy with NO gas (20 ppm) and iloprost (2 ng
· kg1 · min1) decreased circuit-induced platelet dysfunc-
tion and reduced postoperative bleeding in patients sub-
jected to CPB.
Methods
Reagents
Collagen and thrombin receptor-activating peptide (TRAP) were
ameters
NO PGI2 NO  PGI2 P value
8 10 5 —
64 8 65  11 63 9 NS
1.2 8.3 89.8 5.8 85.6 12.3 NS
75 12.8 171 10.4 170 9 NS
2.6 0.5 2.4 0.7 2.6 0.5 NS
2.6 2.6 2.8 NS
4 (50) 6 (60) 3 (60) NS
5 (62) 6 (60) 3 (60) NS
3 (37) 3 (30) 2 (40) NS
6 (75) 7 (70) 4 (80) NS
2 (25) 2 (20) 1 (20) NS
1 (13) 2 (20) 1 (20) NS
3  0.7 2.7  0.5 2.7 0.6 NS
43 7 46  15 45 11 NS
99  29 80  13 83 20 NS
52 14 49  22 48 12 NS
4.6 0.4 4.7  0.4 4.2 0.5 NS
23 15 144 47 105 27 NS
28 21 138 20 100 20 NS
29 22 144 26 104 27 NS
28 23 134 20 106 23 NS
3.3 0.7 3.4 0.5 3.3 0.5 NS
0.3 0.6 0.4 0.6 0.4 0.3 NS
0.2 0.4 0.3 0.2 0.4 0.4 NS
0.6 4.3 9.8  3.1 9.6 3.7 NS
1.2 0.8 1.1 0.7 1.3 1 NS
2.8 1.1 2.7 1.9 2.8 1.2 NS
1.3 0.4 1.7 1.1 1.6 1 NS
0  0 0  0 0  0 NS
0.4 6.8 9  3 10  1.3 NS
2.5 1.4 27 4 21.7 1.3 NS
.31 0.1 0.28 0.14 0.29 0.12 NS
, coronary artery disease; CCS, Canadian Cardiovascular Society; CPB,
intensive care unit; NS, not significant.l par
9
1
1
1
1
1
1
1
2
0
; CADpurchased from Chronolog (Havertown, Pa) and Sigma (St Louis,
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CSPMo), respectively. Fluorescein isothiocyanate (FITC)–conjugated
monoclonal mouse antibodies (MoAbs) directed against glycopro-
tein (GP) IIb (CD41-FITC) and phycoerythrin (PE)–conjugated
MoAbs directed against GPIb (CD42-PE) were from DAKO Di-
agnostics Canada Inc, Mississauga, Ontario, Canada. MoAbs
against activated GPIIb (PAC-1-FITC), P-selectin (CD62P-PE),
leukocyte common antigen (CD45-FITC), and Mac-1 (CD11b-PE)
were from Becton Dickinson (Franklin Lakes, NJ).
Patient Selection and Experimental Design
The Health Research Ethics Board of the University of Alberta,
Edmonton, Canada, approved this study. Informed consent was ob-
tained from all patients before the study. Forty-one patients were
randomly assigned to one of the 4 groups: (1) routine CPB (control);
(2) routine CPB plus NO (20 ppm) administered into the membrane
oxygenator; (3) routine CPB plus iloprost (2 ng · kg1 · min1)
administered into the blood phase of the oxygenator; and (4) routine
CPB plus NO plus iloprost.
All patients included were elective patients scheduled for cor-
onary artery bypass grafting. Excluded were patients undergoing
combined procedures and reoperation. Further exclusion criteria
were evidence for impaired platelet function and coagulation dis-
orders, chronic inflammatory diseases, and renal failure. It was
ensured that platelet inhibitor drugs, such as aspirin or clopidogrel,
were discontinued at least 7 days before the operation.
NO (PulmNOx Medical Inc, Tofield, Alberta, Canada) was
administered into the membrane oxygenator through a Y connector
during the period of extracorporeal circulation. Iloprost (Cayman
Chemical Company, Ann Arbor, Mich) was infused into the oxy-
genator starting from the initiation of CPB and was maintained
throughout the duration of CPB. The doses of NO and iloprost
were selected on the basis of preliminary studies showing signif-
icant effects of these drugs on platelet function without alterations
of hemodynamics (mean arterial blood pressure) or increase in
vasopressor requirement.
For safety reasons, the staff in the operating room, including
Figure 1. Effects of NO and iloprost on CPB-induced
treatments versus control; #P < .05, NO plus iloprost
test).surgeons, perfusionists, and anesthesiologists, was not blinded to
784 The Journal of Thoracic and Cardiovascular Surgery ● Aprithe study. In addition, the exhaust, including the outflow from the
extracorporeal circuit, was removed from the operating room
through central air conditioning. However, the basic scientists
involved in the sample collection, processing, and data analysis
were blinded to the treatment and control groups.
Anesthesia was identical in each group, according to a standard
protocol of the institution, except that aprotinin and all nitrovaso-
dilators were excluded.
The surgical procedure was performed through a midline ster-
notomy, with systemic heparinization and an activating clotting
time well above 400 seconds. All extracorporeal circuits used were
noncoated, were identical in each patient, and consisted of a
membrane oxygenator, arterial filter, and colloidal priming (1400
mL). No patient received aprotinin or other proteinase inhibitors
during the study period. Cardioplegic arrest was performed with
blood cardioplegia.5 The temperature during bypass grafting was
between 32°C and 34°C, and rewarming was initiated after com-
pletion of the last peripheral anastomosis. Reperfusion was per-
formed with whole blood by means of aortic declamping. The
demographic characteristics, clinical parameters of the patients,
number of grafts, reperfusion times, and aortic crossclamp times
are given in Table 1.
Whole blood was withdrawn from the arterial line at 2 time
points: at the onset of CPB (prepump; ie, 5 minutes after heparin
administration) and at the termination of CPB (postpump; ie,
before protamine administration). All blood samples were col-
lected with 3.15% wt/vol trisodium citrate preparation (9:1 vol/
vol) and counted with MicroDiff 16 (Coulter Electronics, Hialeah,
Fla).
The 2 time points selected for analysis of platelet aggregation
and flow cytometry were chosen to study the maximal effects of
CPB on platelet function. We hypothesized that this protocol
would enable us to detect the maximal difference between the
control and treatment groups. In addition, technically it was im-
possible to perform any additional time point analysis on fresh
nges in platelet and leukocyte numbers. *P < .05,
s single treatment (analysis of variance with Dunnettcha
versublood samples because processing the samples would have ex-
l 2005
.05,
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Pceeded the duration of bypass. All data affected by hemodilution
were corrected for it.
Platelet Aggregation
Platelet aggregation was measured by means of whole blood aggre-
gometry with a whole blood ionized calcium lumi-aggregometer
(Chronolog). Changes in impedance (ohm) were recorded as an index
of aggregation. Because blood aggregation depends on many factors,
including red blood cell counts, white blood cell counts, and fibrin-
ogen and plasminogen concentrations in the plasma, the results were
expressed as a percentage of the maximal aggregative response of
each patient.
Flow Cytometry
To determine the relative abundance of GPIb, total-active GPIIb, and
P-selectin, samples were incubated for 20 minutes with saturating
concentrations of FITC– or PE-conjugated antibodies, such as CD42-
PE, CD41-FITC, PAC-1-FITC, or CD62P-PE. The platelet popula-
tion was gated by using forward- and side-scatter parameters. Fluo-
rescence intensity was analyzed with logarithmic scale and
CELLQUEST software. The quantification of GPIb, total-active
GPIIb, and P-selectin levels was expressed as the mean fluorescence
intensity (MFI) from 10,000 individual events. For microparticle
(MP) analysis, samples were incubated with CD42-PE MoAbs, and
the MP population was distinguished by the forward-scatter cutoff
Figure 2. Effects of NO and iloprost on CPB-induced ch
and MPs. *P < .05, treatments versus control; #P <
variance with Dunnett test).that was set to the immediate left of the platelet population. MPs were
The Journal of Thoracireported as the percentage of PE-positive cells. Mac-1 abundance was
analyzed by means of dual-labeling leukocytes with CD45-FITC and
CD11b-PE MoAbs, and the MFI was determined from the FITC-
positive cells. The PLA formation was expressed as 109/L and was
assayed by double-labeling samples with CD45-FITC and CD62P-PE
MoAbs, quantifying the percentage of leukocytes exhibiting CD62P
fluorescence, and multiplying the percentage of PLA by the number
of leukocytes in the samples.
Statistical Analysis
All results were given as means  SEM derived from n determi-
nations and were analyzed by using analysis of variance with the
Bonferroni or Dunnett tests, where appropriate, with Prism soft-
ware (GraphPad Software, Inc, San Diego, Calif).
Results
Effects of CPB on Platelet and Leukocyte Functions
Before the operation, leukocyte and platelet numbers were
6.5  0.5  109 and 2.05  0.25  1011/L, respectively.
The surgical procedure with CPB resulted in a significant
reduction of platelet numbers and an increase in leukocyte
numbers when compared with prepump values (Figure 1).
These changes were associated with increased platelet and
leukocyte activation. In blood samples collected before the
s in platelet receptors (GPIb and total and active GPIIb)
NO plus iloprost versus single treatment (analysis ofangeoperation, the levels of GPIb, total GPIIb, activated GPIIb,
c and Cardiovascular Surgery ● Volume 129, Number 4 785
chan
ent
Cardiopulmonary Support and Physiology Chung et al
CSPP-selectin, and Mac-1 were 850  40, 650  40, 4.5  0.2,
14.8  0.3, and 310  20 MFI, respectively. In addition,
400  20 MPs were detected in 10,000 events, and there
was 2.5 0.1 PLA per 108 platelets. Platelet activation was
evidenced by downregulation of GPIb levels and reduction
of total and active GPIIb levels. In addition, the levels of
MPs were increased (Figure 2). Leukocytes became acti-
vated, as shown by a significant increase of Mac-1 levels
(Figure 3). Furthermore, there was a significant upregula-
tion of platelet-leukocyte interactions as P-selectin and PLA
levels were increased (Figure 3).
The markers of platelet and leukocyte activation in vivo
were accompanied by decreased platelet aggregation in-
duced by collagen and TRAP ex vivo. This was shown by
the right shift of the respective concentration-response
curves (Figure 4, A) and the corresponding increase in
median effective concentration (EC50) values from 1.1 
0.1 to 1.9 0.1 mg/L (collagen) and from 5.9 0.2 to 10.0
 0.1 mol/L (TRAP; P  .05).
Effects of NO on CPB-induced Platelet Activation and
Platelet-leukocyte Activation
In the presence of NO, platelet counts remained reduced;
Figure 3. Effects of NO and iloprost on CPB-induced
control; #P < .05 NO plus iloprost versus single treatmhowever, this reduction was significantly attenuated com-
786 The Journal of Thoracic and Cardiovascular Surgery ● Apripared with levels in the nontreated group (Figure 1). The
NO treatment failed to prevent the significant increase in
leukocyte numbers (Figure 1).
The panel of CPB-induced markers of platelet activation,
such as GPIb and GPIIb downregulation and MP formation,
were significantly attenuated by NO (Figure 2). In addition,
there was decreased leukocyte activation and formation of
PLA (Figure 3), as demonstrated by reduced Mac-1, P-
selectin, and PLA levels.
Platelet aggregation showed that although the aggrega-
tive responses to collagen were preserved by the NO treat-
ment (EC50 postpump value of 1.2  0.1 vs prepump value
of 1.3  0.2 mg/L, P  .05), TRAP-induced aggregation
remained decreased (EC50 postpump value of 14.2  2.8 vs
prepump value of 5.6  0.2 mol/L, P  .05).
Effects of Iloprost on CPB-induced Platelet-leukocyte
Activation
With the use of iloprost, platelet numbers were reduced by
14%  2%, which was less than those in control subjects.
Iloprost exerted no significant effects on leukocytosis (in-
crease by 92%  25%, Figure 1).
However, iloprost attenuated the effects of CPB on
ges in Mac-1, P-selectin, and PLA. *P < .05 versus
(analysis of variance with Dunnett test).GPIb, GPIIb, activated GPIIb, MP, and P-selectin. In con-
l 2005
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Ptrast, the treatment enhanced the effects of CPB on Mac-1
and PLA (Figures 2 and 3). Aggregation to collagen was
preserved (EC50 postpump value of 1.2  0.2 vs prepump
value of 1.4  0.1 mg/L, P  .05), whereas that to TRAP
remained decreased (EC50 postpump value of 13.8  1.1 vs
prepump value of 6.3  0.3 mol/L, P  .05).
Effects of NO plus Iloprost on CPB-induced Platelet-
leukocyte Activation
The combination therapy effectively prevented thrombocy-
topenia but did not prevent leukocytosis (Figure 1). The
drugs attenuated the effects of CPB on GPIb, total GPIIb,
MP, P-selectin, Mac-1, and PLA (Figures 2 and 3).
Interestingly, aggregation to collagen and TRAP were
Figure 4. CPB-induced changes in platelet aggregati
iloprost (B). *P < .05, treatments versus control (analywell preserved (Figure 4, B).
The Journal of ThoraciEffects of NO and Iloprost on Chest Tube Loss
Figure 5 shows the effects of treatments with NO and
iloprost on chest tube blood loss after cardiac surgery. Both
NO and NO plus iloprost, but not iloprost alone, signifi-
cantly attenuated this blood loss.
Discussion
We investigated platelet- and leukocyte-related mechanisms
of CPB-induced postoperative bleeding. A very high effec-
tiveness of combinations of NO and PGI2 in attenuating
platelet activation in vitro4,6 prompted us to design a pilot
clinical study to evaluate the effects of these inhibitors on
platelet-leukocyte function and postoperative bleeding in
patients subjected to coronary revascularization with CPB.
The major novel findings of our investigation showed
collagen and TRAP (A) and the effects of NO plus
f variance with Dunnett test).on to
sis othat the combined treatment with NO and iloprost (1) abol-
c and Cardiovascular Surgery ● Volume 129, Number 4 787
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CSPished the CPB-induced thrombocytopenia, (2) prevented the
loss of platelet aggregation to collagen and TRAP, and (3)
reduced postoperative bleeding.
CPB and Platelet-leukocyte Dysfunction
The increased tendency for hemorrhage in patients under-
going cardiac surgery with CPB is likely to be multifacto-
rial; it involves thrombocytopenia, increased coagulation,
fibrinolysis, complement activation, and inflammation. In
addition, it is known that pump and clamp times, as well as
flow rates, are important determinants of platelet and leu-
kocyte activation and function. In this regard a recent study
by Greilich and colleagues7 showed that prolongation of
CPB is related to increasing degrees of platelet dysfunction
and that reductions in platelet contractile force are related to
decreases in platelet adhesion receptors and early postoper-
ative blood loss. This pathologic scenario is often associated
with the postoperative need for transfusion of blood prod-
ucts and the requirement for inotropic support, both of
which are risk factors for morbidity and mortality.2
Previous studies and the current investigation show that
thrombocytopenia is a major contributing factor to CPB-
induced bleeding.2,8,9 Early hemodilution caused by the
crystalloid fluid for priming of the extracorporeal circuit
might partially explain this phenomenon. However, Hollo-
way and coworkers9 suggested that the mechanical disrup-
tion of platelets by shear forces (oxygenator) and increased
platelet adhesion to the extracorporeal membrane and se-
questration in organs both contribute to the true decrease in
circulating platelet numbers. Our study provides a compel-
ling indication for in-circuit activation of platelets. This is
evidenced by a large increase in MP formation that derives
from the membrane of activated platelets,10 downregulation
of GPIb that results from its internalization,11 and the trans-
location of platelet -granule P-selectin to the surface of
Figure 5. Chest tube blood loss after CPB and the effects of NO
and iloprost. *P < .05, treatments versus control (analysis of
variance with Dunnett test).activated platelets.12 Downregulation of total and active
788 The Journal of Thoracic and Cardiovascular Surgery ● ApriGPIIb provides a strong rationale for the proposal that
circuit-activated platelets are exhausted and no longer ca-
pable of responding with aggregation to hemostatic regula-
tors in vivo.1 This hemostatic defect can be exposed by ex
vivo adhesion and aggregation studies that demonstrated
impaired platelet reactivity to collagen, thrombin,13-15 and,
as shown in the current study, TRAP. Therefore the major
mechanisms of CPB-related postoperative bleeding are both
functional (platelet reactivity) and quantitative (platelet
count) defects.13,16
We and others have shown that thrombocytopenia is
accompanied by leukocytosis that is associated with the
inflammatory response.17 The surfaces of CPB systems (ie,
oxygenator and tubing) are recognized as foreign by the
immune system, which subsequently activates a cytokine
cascade.18 Cytokines initiate systemic inflammatory reac-
tions, leading to leukocyte recruitment and activation and
generation of oxidants and radicals, such as superoxide.
Clinically, these reactions result in systemic vasodilation,
increased vascular permeability, and organ dysfunction.
The role of platelets in CPB-induced inflammation is not
clear; however, PLA might play a critical role in this pro-
cess. Indeed, activated platelets translocate P-selectin to
their surface, whereas Mac-1 (CD11b/CD18) is upregulated
by activated leukocytes. The interactions of these adhesion
receptors with their ligands19-21 facilitate PLA formation,
endothelial adhesion, and inflammatory leukocyte extrava-
sation. Increased Mac-1 and P-selectin levels in conjunction
with enhanced PLA during CPB are well evidenced by our
study. Therefore, simultaneous activation of both platelets
and leukocytes with platelet adhesion, aggregation, and
PLA can all contribute to circuit-induced thrombocytope-
nia, inflammatory responses, and increased postoperative
blood loss. It is important to note that in the present study no
differences between the control and treatment groups with
regard to pump and clamp times, as well as flow rates, were
observed (Table 1).
Effects of NO or Iloprost on CPB
We also demonstrated the protective effects of NO and
iloprost on platelet function. Both drugs protected platelets
from activation, as evidenced by attenuation of thrombocy-
topenia and inhibition of changes in platelet receptors. Be-
cause NO and PGI2 and its analog iloprost are well-known
regulators of platelet activation and inhibit platelet adhesion
and aggregation at various levels of the activating cascade,4
the effectiveness of these drugs in limiting platelet damage
is not surprising.
Indeed, the beneficial effects of NO and PGI2 have also
been demonstrated in other studies. Aren and associates22
showed that PGI2 infusion into the bypass circuit reduced
plasma -thromboglobulin levels, reflecting inhibition of plate-
let activation, although the dosage used (50 ng · kg1 · min1)
l 2005
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Mellgren and colleagues23 demonstrated higher platelet counts
in experimental perfusion circuits treated with NO (15-75
ppm); however, platelet function was not measured in this
study. Inhaled NO downregulated P-selectin, platelet aggrega-
tion, and fibrinogen binding in patients with severe adult re-
spiratory distress syndrome,24 but the concentration of NO
(100-884 ppm) was again much higher than in our study (20
ppm). Furthermore, extracorporeal circuits coated with NO
release polymers reduced platelet consumption in experimental
animals.25 The protective effects of NO and PGI2 in CPB,
however, are not without considerable debate. PGI2 infusion
might cause hypotension,26 suggesting that the use of high
amounts of these potent platelet inhibitors is likely to affect the
hemodynamic balance by increasing vasodilatation and vascu-
lar permeability. Therefore the use of small (nonvasodilator)
amounts of NO and iloprost (that proved to be efficacious in
our study) applied directly to the oxygenator might be prefer-
able in the quest to limit the CPB-induced platelet activation
and damage.
Interestingly, the iloprost treatment increased Mac-1 lev-
els in white blood cells. In contrast to platelets, where
stimulation with antiaggregative prostaglandins, such as
prostacyclin and prostaglandin D2, invariably leads to
downregulation of integrin function, the effects of prosta-
glandins on white blood cells appear to be more complex.
Indeed, prostaglandin D2 stimulates chemotaxis and Mac-1
expression27 in eosinophils through activation of a novel
DP2 receptor. Thus, the stimulator effects of iloprost on
Mac-1 could reflect activation of the DP2 receptor in white
blood cells.
Effects of NO plus Iloprost on CPB
The major interest of our study has been focused on the
combined use of NO and iloprost during CPB. The in vitro
studies clearly showed that NO and PGI2 synergize with
each other as inhibitors of platelet aggregation and inducers
of deaggregation. The current study has shown that the most
striking advantage of using this combination of low doses of
NO and iloprost is total prevention of thrombocytopenia and
normalization of circuit-induced aggregative dysfunction.
NO plus iloprost also reduced postoperative blood loss;
however, in this action NO was as efficacious as the com-
bination. The protective effects afforded by NO plus ilo-
prost correlated well with reduction of MP and P-selectin
levels. However, no additional protection over that seen
with single-drug treatment could be detected with GPIb and
GPIIb measurements. The reason or reasons for this dis-
crepancy are not known.
Mechanisms of Platelet-protective Effects of NO
and Iloprost
NO and iloprost inhibit platelet activation by stimulating the
intraplatelet levels of cyclic guanosine monophosphate
The Journal of Thoraci(cGMP) and cyclic adenosine monophosphate (cAMP), re-
spectively.4 Indeed, increase of intracellular cAMP and
cGMP levels is the most potent endogenous mechanism of
platelet inhibition. Cyclic nucleotides control a number of
platelet functions, such as inhibition of intracellular Ca2
increase, cytoskeletal reorganization, integrin receptor acti-
vation, granule secretion, surface molecule expression, and
mitogen-activated protein kinase function.28 All these ef-
fects result in inhibition of platelet activation. There is also
evidence that the cAMP and cGMP pathways cross-talk to
inhibit platelet activation. Cyclic GMPmediated inhibi-
tion of cAMP hydrolysis through reduction of phosphodi-
esterase 3 activity might be one of the mechanisms that
account for the synergistic interactions between NO and
iloprost on platelets.28,29
As with single-compound treatment, the combined ther-
apy exerted no significant effects on leukocytosis and only
weakly affected Mac-1 and PLA levels. Thus other phar-
macologic strategies should be used to decrease further
circuit-induced inflammatory reactions.
Clinical Implications of the Present Study
The most important clinical aspect to be derived from the
present findings is the potential for significant reduction in
postoperative bleeding by means of preservation of platelet
function. This might be even more pronounced in the setting
of prolonged pump time or in patients receiving long-term
extracorporeal support, including extracorporeal membrane
oxygenation and assist devices. Indeed, Jacobson30 has re-
cently pointed out that NO is a potent platelet protectant
against a significant reduction in platelet number and func-
tion, as observed in patients requiring long-term mechanical
support.
Another important aspect of the use of the combina-
tion of NO and iloprost is cost-effectiveness. In our
center the average cost for such therapy per one patient is
$25 for NO and $15 for iloprost, assuming a pump time
of 60 minutes. Given the potential saving effect on blood
products with this treatment strategy, the overall cost
might be reduced.
Study Limitations
We acknowledge that there are limitations of this pilot
clinical study. The first is the relatively small number of
patients in the treatment groups. However, our study was of
sufficient statistical power to delineate differences in plate-
let function and platelet-leukocyte interactions between the
control and treatment groups. Furthermore, the conclusions
of our study are based not on the analysis of single variable
but on the use of a panel of molecular (GP receptors, MPs,
P-selectin, and Mac-1 levels), functional (platelet aggrega-
tion and platelet-leukocyte aggregation), and clinical (plate-
let and leukocyte numbers and postoperative blood loss)
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CSPvariables. This analysis clearly shows the protective effects
on platelets and the resultant clinical benefits (reduction of
thrombocytopenia and postoperative blood loss) of nonva-
sodilator amounts of NO and iloprost.
Second, in this study we focused only on the acute
effects of NO and iloprost on blood cells. It is possible that
longer treatment regimens would have additional beneficial
effects on postoperative bleeding or other thrombotic and
inflammatory complications of CPB. In addition, in the
present study no differences were observed between groups
with regard to the administration of blood products. One
reason might be that the patients included in our study were
elective patients, excluding those scheduled for repeat op-
erations and those expected to have long pump times. Thus
the present study was performed in a selected group of
patients not at high risk for major bleeding disorders. How-
ever, one can speculate that the finding of reduced chest
tube loss and the platelet-sparing effect with NO and ilo-
prost, as shown in the present study, might be even more
pronounced in larger trials with higher-risk patients and
prolonged CPB procedures, resulting in reduction of trans-
fusion requirements.
In summary, the present study demonstrates, for the first
time, that combined treatment with low amounts of NO (20
ppm) or iloprost (2 ng · kg1 · min1), when delivered into
the oxygenator, reduced thrombocytopenia, normalized
platelet aggregation, and attenuated postoperative blood
loss, providing a safe method to decrease bleeding in pa-
tients subjected to CPB.
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